BNET Industries

Sucampo Pharmaceuticals Inc.

(SCMP) is in the Pharma Industry

Market Cap:$54.3M
Last Fiscal Year Sales:$112.1M
  • Public
  • US
Dow Jones Description

We are an international biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. In January 2006, we received marketing approval from the U.S. Food and Drug Administration, or FDA, for our first product, Amitiza ® (lubiprostone), for the treatment of chronic idiopathic constipation, or CIC, in adults. In April 2008, the FDA approved Amitiza for its second indication for the treatment of irritable bowel syndrome with constipation, or IBS-C, in adult women. We are currently developing Amitiza for the treatment of opioid-induced bowel dysfunction, or OBD. In the United States and Canada, Amitiza is being marketed and developed under a collaboration and license agreement with Takeda Pharmaceutical Company Limited, or Takeda, for gastrointestinal indications. Under the agreement with Takeda, we are primarily responsible for the research and development of Amitiza, while Takeda is primarily responsible for the commercialization and marketing activities. Additionally, Takeda funds the majority of our research and development activities in the United States and part of the co-promotion activities of our own sales force, per the terms of the agreement. Takeda records all product revenue and we receive a royalty on such product sales. ...

Number of Employees 94
Contact Information

4520 East West Hwy 3rd Fl

Bethesda, Maryland 20814

sucampo.com

(301) 961-3400

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Sucampo Pharmaceuticals Releases Financial Results for 3Q 2009

    11/10/09 - Financial Announcement - View Story

  • Sucampo Pharmaceuticals Reports Financial Results for the Third Quarter of 2009

    11/05/09 - Board Member - Entering - View Story

  • Sucampo Appoints William L. Ashton to Board of Directors

    10/20/09 - Board Member - Entering - View Story

  • Sucampo Pharmaceuticals SCMP Appoints James J. Egan as COO

    9/14/09 - Mgmt. Change Entering - Other - View Story

  • Sucampo Adds Chief Operating Officer and Names New Presidents at Americas and European Subsidiaries

    9/16/09 - Board Member - Entering - View Story

  • Sucampo Pharmaceuticals, Inc. Withdraws European Marketing Application for Lubiprostone

    9/04/09 - Product Announcement - View Story

  • Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. JOBS Bowel Drug Lubiprostone Produces Mixed...

    7/23/09 - Product Announcement - View Story

News & Analysis

seeking alpha and sucampo pharmaceuticals inc. - All News and Analysis

advertisement
     SCMP $3.47 -0.13 (-3.61% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 41,622
Shares Outstanding 15.65M
Market Cap 54.3M
Year High 8.78
Year Low 2.74
Earnings Per Share -0.13
P/E Ratio -26.69
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement